MedTrace Logo

HRD Status Reference Standard Based on WGS

NCT06490380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-07-08

No results posted yet for this study

Summary

When evaluating the analytical performance of homologous recombination deficiency (HRD) status testing, there is currently no widely accepted reference standard. Therefore, a collaborative project was initiated to establish a HRD status reference standard for the industry. Although there is no genotyping strategy that is universally recognized as the most accurate for evaluating HRD status, whole-genome sequencing (WGS) is one of the best candidates.

Conditions

Interventions

DRUG

PARPi

Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)

Sponsors & Collaborators

  • National Institutes for Food and Drug Control, China

    collaborator OTHER

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Lei Li

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-30
Primary Completion
2023-12-13
Completion
2024-06-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490380 on ClinicalTrials.gov